I am starting to now believe - rather than hope, that all 4 of the current phase 2 trials will be successful.
Similar ailments treated by the same drug.
Efficacy is the only real variant.
And then phase 3 - with this science? With this management team - I believe they will be successul too (albeit with the fact that Neuren themselves have not as yet got a drug past phase 3).
They must have learnt something with Trofinetide regarding that! And they have plenty of cash to hire/contract the right people to do the job.
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-7
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.07 |
Change
-0.400(2.76%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $14.47 | $14.53 | $13.99 | $7.843M | 552.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2150 | $14.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.10 | 1129 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |